Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa.

× No keyword cloud information.

15 in total

1. A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection.

Authors: Ana Fernández-Cruz; Natalia Alba; María Auxiliadora Semiglia-Chong; Belén Padilla; Gabriela Rodríguez-Macías; Mi Kwon; Emilia Cercenado; Esther Chamorro-de-Vega; Marina Machado; Laura Pérez-Lago; Darío García de Viedma; José Luis Díez Martín; Patricia Muñoz
Journal: Antimicrob Agents Chemother Date: 2019-01-29 Impact factor: 5.191

2. Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.

Authors: Laura Escolà-Vergé; Carles Pigrau; Ibai Los-Arcos; Ángel Arévalo; Belen Viñado; David Campany; Nieves Larrosa; Xavier Nuvials; Ricard Ferrer; Oscar Len; Benito Almirante
Journal: Infection Date: 2018-03-28 Impact factor: 3.553

3. Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.

Authors: Sarah C J Jorgensen; Trang D Trinh; Evan J Zasowski; Abdalhamid M Lagnf; Samuel P Simon; Sahil Bhatia; Sarah M Melvin; Molly E Steed; Natalie A Finch; Taylor Morrisette; Sandy J Estrada; Joshua R Rosenberg; Susan L Davis; Michael J Rybak
Journal: Antimicrob Agents Chemother Date: 2020-03-24 Impact factor: 5.191

4. Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.

Authors: Morgan Hakki; James S Lewis
Journal: Infection Date: 2018-02-19 Impact factor: 3.553

Review 5. New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors: Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal: Clin Microbiol Rev Date: 2020-11-11 Impact factor: 26.132

6. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.

Authors: Mariana Castanheira; Leonard R Duncan; Rodrigo E Mendes; Helio S Sader; Dee Shortridge
Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191

7. Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model.

Authors: Veronica Rico Caballero; Safa Almarzoky Abuhussain; Joseph L Kuti; David P Nicolau
Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191

8. Ceftolozane-tazobactam and Fosfomycin for rescue treatment of otogenous meningitis caused by XDR Pseudomonas aeruginosa: Case report and review of the literature.

Authors: Antonella Frattari; Vincenzo Savini; Ennio Polilli; Donatella Cibelli; Silvia Talamazzi; Donatella Bosco; Augusta Consorte; Paolo Fazii; Giustino Parruti
Journal: IDCases Date: 2018-08-31

Review 9. Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data.

Authors: Silvia Garazzino; Elena Altieri; Erika Silvestro; Giulia Pruccoli; Carlo Scolfaro; Elisabetta Bignamini
Journal: Front Pediatr Date: 2020-05-05 Impact factor: 3.418

Review 10. Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence.

Authors: Luca Gregorio Giaccari; Maria Caterina Pace; Maria Beatrice Passavanti; Francesca Gargano; Caterina Aurilio; Pasquale Sansone
Journal: Life (Basel) Date: 2021-05-24